Skip to main content
DPRXinactive

PLX PHARMA INC.

·Commercial·CEO: Natasha Giordano
CardiovascularPain

DPRX evidence brief

What we can confirm

BioSniper Score:
8.0 / 10
Lead Asset:
pl1100 (Phase 1)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 8.0 / 10 · Lead Asset: pl1100 (Phase 1)
BioSniper AIPage evidence connected

Prepared research question

What matters most for DPRX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

8.0/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

pl1100 (Phase 1)

Next Catalyst

—

Tracking 3 pipeline candidates · 1 FDA decision for PLX PHARMA INC..

Run PLX PHARMA INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available PLX PHARMA INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is PLX PHARMA INC.'s lead drug candidate?

PLX PHARMA INC.'s most advanced tracked candidate is pl1100 (Phase 1) for pain and inflammation.

Who is the CEO of PLX PHARMA INC.?

Natasha Giordano is the chief executive officer of PLX PHARMA INC. (DPRX).

What therapeutic areas does PLX PHARMA INC. focus on?

PLX PHARMA INC. develops therapies across Cardiovascular, Pain.

923 companies304,846 SEC filings22,651 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.